# Solstice Neurosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/solstice-neurosciences

- Industry: Biotechnology
- Headquarters: South San Francisco, US
- Website: www.solsticeneuro.com
- Total disclosed funding: $45M
- Latest round: Series B (Nov 8, 2006)
- Investors on record: 5

## About

Solstice Neurosciences is a biotechnology company focused on developing innovative therapeutic solutions for patients with neurological disorders and unmet medical needs, emphasizing patient care and quality of life improvements.Solstice Neurosciences specializes in the research and development of drugs targeted at neurological conditions. The company was acquired by US WorldMeds in August 2010 for USD 35.70 mn. It is located in South San Francisco, US, and has been involved in 4 deals since its inception.Solstice Neurosciences produces a range of innovative therapeutics aimed at treating patients with neurological disorders. Their core offerings include prescription medications that target chronic health issues, improving patient outcomes across diverse markets, including the US, Europe, and parts of Asia. The company collaborates with healthcare providers, hospitals, and specialty pharmacies to ensure access to effective treatment options.Revenue is generated primarily through the distribution of pharmaceutical products via partnerships with wholesalers and specialty pharmacies. Solstice Neurosciences' transaction structure is based on B2B relationships with healthcare providers, ensuring that products meet the specific needs of patients while adhering to competitive pricing and regulatory standards.Solstice Neurosciences aims to expand its product line with new therapeutic offerings, although specific upcoming products have not been disclosed. The company is exploring opportunities for market entry into additional geographic regions beyond its current operations, leveraging insights gained from its acquisition by US WorldMeds. Funding from the USD 35.70 mn Trade Sale in August 2010 will be allocated to support these initiatives and strengthen its position in the healthcare market.

## Funding rounds

- Series B, Nov 8, 2006, $45M — Highland Capital Partners, Oxford Bioscience Partners, Thomas, McNerney & Partners, Patricia Industries, MSDW Venture Partners

## Investors

- Highland Capital Partners (https://capitalatlas.ai/funds/highland-capital-partners) — Series B
- Oxford Bioscience Partners (https://capitalatlas.ai/funds/oxford-bioscience-partners) — Series B
- Thomas, McNerney & Partners (https://capitalatlas.ai/funds/thomas-mcnerney-partners) — Series B
- Patricia Industries (https://capitalatlas.ai/funds/patricia-industries) — Series B
- MSDW Venture Partners (https://capitalatlas.ai/funds/msdw-venture-partners) — Series B